Publications by authors named "Marcel Am Beijk"
Second-generation drug-eluting stents (DES) are considered standard of care for revascularization of patients undergoing percutaneous coronary intervention. Besides the polymer and antiproliferative drug used, the metallic backbone of DES is an attractive target for further development. Ultrathin-strut DES (≤70 μm strut thickness) are more flexible, have an improved trackability and crossability compared to conventional second-generation DES.
View Article and Find Full Text PDFP2Y-inhibitor monotherapy after coronary stenting: are all P2Y-inhibitors equal?
Expert Rev Cardiovasc Ther
August 2022
Article Synopsis
- P2Y-inhibitor monotherapy after 1-3 months of dual antiplatelet therapy (DAPT) is a promising alternative to longer DAPT durations following percutaneous coronary intervention (PCI), as it reduces major bleeding without increasing ischemic events.
- The review evaluates the effectiveness of different P2Y-inhibitors—clopidogrel, prasugrel, and ticagrelor—highlighting that ticagrelor is often the preferred choice based on its consistent effect in trials.
- Future studies should focus on determining the ideal duration of initial DAPT and identifying the best long-term antithrombotic therapy beyond 12 months.
Background: In this study, we discovered and validated candidate microRNA (miRNA) biomarkers for coronary artery disease (CAD).
Method: Candidate tissue-derived miRNAs from atherosclerotic plaque material in patients with stable coronary artery disease (SCAD) (n=14) and unstable coronary artery disease (UCAD) (n=25) were discovered by qPCR-based arrays. We validated differentially expressed miRNAs, along with seven promising CAD-associated miRNAs from the literature, in the serum of two large cohorts (n=395 and n=1000) of patients with SCAD and UCAD and subclinical atherosclerosis (SubA) and controls, respectively.